ARS PHARMACEUTICALS INC (SPRY) Stock News

NASDAQ:SPRY - US82835W1080 - Common Stock

10.88 USD

-0.24 (-2.16%)

Last: 9/3/2025, 8:00:02 PM

10.75 USD

-0.13 (-1.19%)

After Hours: 9/3/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SPRY Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

21 days ago - By: The Motley Fool

ARS Pharma Sales Jump 3,040% in Q2

22 days ago - By: Zacks Investment Research - Mentions: NTRB

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates

22 days ago - By: Benzinga

Earnings Outlook For ARS Pharmaceuticals

4 months ago - By: Benzinga

ARS Pharmaceuticals's Earnings: A Preview

22 days ago - By: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

22 days ago - By: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

23 days ago - By: Zacks Investment Research - Mentions: FDMT

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates

a month ago - By: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

a month ago - By: Zacks Investment Research - Mentions: CORT

Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates

a month ago - By: Zacks Investment Research

Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for

2 months ago - By: ARS Pharmaceuticals, Inc.

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

2 months ago - By: ARS Pharmaceuticals, Inc.

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

3 months ago - By: Yahoo Finance - Mentions: JPM MEOH TJX AMTM ...

JPMorgan Initiates Coverage on Methanex (MEOH) Stock

3 months ago - By: Yahoo Finance - Mentions: ESE PZZA TMO SBUX ...

Jim Cramer on ESCO Technologies: “I Find This One Intriguing”

3 months ago - By: Yahoo Finance - Mentions: TFC GEV UNP SPG ...

Jim Cramer on Truist: “I Would Hang On to This One”

3 months ago - By: Yahoo Finance - Mentions: KR UBS UNP BMRN ...

Jim Cramer on Kroger: “Do Not Buy All At Once”

3 months ago - By: Yahoo Finance - Mentions: HD SHW UNP LOVE ...

Jim Cramer Recommends Home Depot Over Sherwin-Williams

3 months ago - By: Yahoo Finance - Mentions: UNP SPG KR GSC ...

Jim Cramer on Union Pacific: “I Think It’s a Really Good Stock to Own”

3 months ago - By: Yahoo Finance - Mentions: ARQT MEOH GSC KR ...

Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”

3 months ago - By: Yahoo Finance - Mentions: SMR GS KR GSC ...

Jim Cramer on Nuscale Power: “I’d Wait for the Stock Offering”

3 months ago - By: Yahoo Finance - Mentions: AMTM SMR TJX MEOH ...

Jim Cramer Says “Amentum’s Definitely Worth Keeping on Your Radar”

3 months ago - By: Yahoo Finance - Mentions: COST TJX JPM MEOH ...

Jim Cramer Notes TJX Stock Drops Despite Strong Quarter

3 months ago - By: Yahoo Finance - Mentions: IVZ VZ QQQ O ...

The Smartest Tech ETF to Buy With $1,000 Right Now

3 months ago - By: Yahoo Finance - Mentions: SPG VZ UBER COIN ...

How Much Would It Take To Earn $100 A Month From Simon Property Stock

3 months ago - By: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

3 months ago - By: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

4 months ago - By: Zacks Investment Research - Mentions: PRPH

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates

4 months ago - By: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

4 months ago - By: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

4 months ago - By: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

4 months ago - By: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

4 months ago - By: ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians